Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of sa-mRNA Influenza Vaccine in Healthy Adults
NCT06028347Phase 1Completed
- Sponsor
- CSL Seqirus
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of saRNA influenza vaccine in influenza (4 arms), sponsored by CSL Seqirus. Primary endpoints: Number and percentage of subjects with clinically significant abnormal vital signs and/or acute reactions, Number and percentage of subjects reporting reactogenicity: Solicited local and systemic AEs and 8 more. Started Oct 2023; status: completed.
02
Drugs
saRNA influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06028347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028347.